None listed
Conditions
Interventions
None listed
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male or female adult patients aged 18 years old and above 2. Patients who were diagnosed as locally advanced or metastatic NSCLC from Jan 2011 3. Patients who were diagnosed as histologically or cytologically ALK positive adenocarcinoma 4. Patients who initiated crizotinib as a first-line therapy and experienced disease progression (definitive CCRT, neoadjuvant or adjuvant chemotherapy prior to crizotinib are allowed) 5. Patients who were treated with crizotinib for at least 84 days 6. Patients who are eligible to evaluate response to brigatinib or alectinib 7. Patients who provide written informed consent for the study
Exclusion criteria
Exclusion criteria: 1. Patients who were treated with ALK inhibitors other than alectinib or brigatinib after crizotinib failure 2. Patients who stopped a first-line crizotinib treatment for other than disease progression 3. Patients who received chemotherapy in between crizotinib and 2nd line ALK inhibitor 4. Patients whose medical records are not available for review
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS) | — |
Secondary
| Measure | Time frame |
|---|---|
| objective response rate (ORR), intracranial objective response rate (IC-ORR), duration of response (DR), intracranial duration of response (IC-DR), time to progression (TTP), intracranial time to progression (IC-TTP), and extracranial time to progression (EC-TTP);disease control rate (DCR) and intracranial disease control rate (IC-DCR) at 6 and 12 weeks;Safety and tolerability | — |
Countries
Korea, Republic of
Contacts
Public ContactChang-Min Choi
Asan Medical Center
Outcome results
None listed